Obesity Drug
Roche’s Patent License Deal with Structure Therapeutics for CT-996 Obesity Drug
Roche; Structure Therapeutics; patent license; CT-996; obesity drug; Genentech; GLP-1
Lilly Slightly Lowers Self-Pay Prices for Single-Dose Vials of Zepbound
Eli Lilly; Zepbound; price cut; self-pay; single-dose vials; direct-to-consumer; LillyDirect; obesity drug; GLP-1
Lilly Prepares Amylin-Based Obesity Drug Eloralintide for Phase III After Strong Weight Loss Results
Eli Lilly; eloralintide; amylin agonist; obesity drug; Phase III trial; weight loss; clinical development
Terns Ditches Obesity Pill After Phase 2 Letdown, Shifts Focus to Cancer Pipeline
Terns Pharmaceuticals; TERN-601; obesity drug; GLP-1 receptor agonist; Phase 2 trial; weight loss; liver enzyme elevation; oncology; TERN-701; chronic myeloid leukemia (CML); metabolic disease
Kailera Raises $600 Million to Launch Global Phase III Program for Obesity Drug
Kailera; obesity drug; Phase III clinical trial; KAI-9531; GLP-1/GIP dual agonist; Series B financing; Bain Capital; weight loss therapy; clinical pipeline; biotech funding